Affimed (AFMD) Announces Presentation of Preclinical AFM13 Data; Improved NK-Cell Cytotoxicity Noted
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Affimed N.V. (Nasdaq: AFMD) announced the presentation of preclinical data on the Company’s lead candidate AFM13, a bispecific NK-cell-engaging TandAb targeting CD30/CD16A, at the 16th Annual Meeting of the Society for Natural Immunity in Taormina, Italy.
The data, generated in Affimed’s collaboration with the Innate Immunity Group of Dr. Adelheid Cerwenka at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, were presented in a poster titled “The bispecific CD30/CD16A TandAb AFM13 amplifies the cytolytic and proliferative potential of NK-cells” yesterday, October 3, 2016.
In this preclinical study, the specific phenotype and functionality of human NK-cells when redirected to AFM13-coated tumor cells, as well as their responsiveness to cytokines, were analyzed. The results show that AFM13 improves NK-cell cytotoxicity against CD30+ tumor cells that are resistant to naïve NK-cells. Using CFSE-labelled NK-cells, the researchers demonstrated that AFM13 amplifies cytokine–mediated NK-cell proliferation and expansion by enhancing the NK-cells’ sensitivity to IL-2 and IL-15. These data indicate that cytokine administration in combination with AFM13 might potentially enhance NK-cell activity in the tumor microenvironment.
AFM13 is a tetravalent bispecific TandAb antibody that binds bivalently to both CD30 on tumor cells and CD16A on NK-cells. The molecule has been shown to engage NK-cells through CD16A with high affinity and specificity, resulting in strong NK-cell-mediated cytotoxicity. AFM13 is currently being tested in Hodgkin lymphoma patients as a monotherapy (Phase 2) and in combination with Merck’s Keytruda® (Phase 1b).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Minerva Neurosciences (NERV) Reports Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia
- Bioptix (BIOP) to Terminate Some Employees Associated with Acquisition of its Subsidiary
- Rexahn Pharma (RNN) Presents Update of Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at ASCO
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!